Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

An overview of international regulatory frameworks for mesenchymal stromal cell‐based medicinal products: From laboratory to patient

  • López-Beas, Javier
  • Guadix, Juan Antonio
  • Clares Naveros, Beatriz
  • Soriano-Ruiz, José Luis
  • Zugaza, José L.
  • Gálvez Martín, Patricia
Human mesenchymal stromal cells (hMSCs) are emerging as one of the most important cell types in advanced therapies and regenerative medicine due to their great therapeutic potential. The development of hMSC‐based products focuses on the use of hMSCs as biological active substances, and they are considered medicinal products by the primary health agencies worldwide. Due to their regulatory status, the development of hMSC‐based products is regulated by specific criteria that range from the design phase, nonclinical studies, clinical studies, to the final registration and approval. Patients should only be administered hMSC‐based products within the framework of a clinical trial or after the product has obtained marketing authorization; in both cases, authorization by health authorities is usually required. Considering the above, this paper describes the current general regulatory requirements for hMSC‐based products, by jurisdiction, to be implemented throughout their entire development process. These measures may provide support for researchers from both public and private entities and academia to optimize the development of these products and their subsequent marketing, thereby improving access to them by patients., This study was supported by the Spanish Ministry of Science, Innovation and Universities (MICIU), State Plan for Scientific and Technical Research and Innovation, Grant/Award No: RTI2018‐095410‐BI00; Spanish Ministry of Economy, Industry and Competitiveness (MINECO), Grant/Award No: RD16/0011/0030; MICIU (to JAG) and MINECO (FEDER funds, project RTC‐2016‐5451‐1) (to BC and PG‐M). Furthermore, this study has been also developed in the context of AdvanceCat with the support of ACCIÓ (Catalonia Trade & Investment; Generalitat de Catalunya) under the Catalonian European Regional Development Fund operational program, 2014 to 2020 (to PG‐M)., Peer reviewed